BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 33821344)

  • 21. The Prognostic Value of Axillary Staging Following Neoadjuvant Chemotherapy in Inflammatory Breast Cancer.
    Grova MM; Strassle PD; Navajas EE; Gallagher KK; Ollila DW; Downs-Canner SM; Spanheimer PM
    Ann Surg Oncol; 2021 Apr; 28(4):2182-2190. PubMed ID: 32974693
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Toward omitting sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with clinically node-negative breast cancer.
    van der Noordaa MEM; van Duijnhoven FH; Cuijpers FNE; van Werkhoven E; Wiersma TG; Elkhuizen PHM; Winter-Warnars G; Dezentje V; Sonke GS; Groen EJ; Stokkel M; Vrancken Peeters MTFD
    Br J Surg; 2021 Jun; 108(6):667-674. PubMed ID: 34157085
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla.
    Bi Z; Liu J; Chen P; Liu Y; Zhao T; Wang C; Zhang Z; Sun X; Qiu P; Cong B; Song X; Wang Y
    Breast Cancer; 2019 May; 26(3):373-377. PubMed ID: 30666563
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of Elective Nodal Irradiation in Patients With ypN0 After Neoadjuvant Chemotherapy Followed by Breast-Conserving Surgery (KROG 16-16).
    Cho WK; Park W; Choi DH; Kim YB; Kim JH; Kim SS; Kim K; Kim JH; Ahn SJ; Lee SY; Lee J; Kim SW; Kwon J; Ahn KJ
    Clin Breast Cancer; 2019 Feb; 19(1):78-86. PubMed ID: 30241965
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neoadjuvant Chemotherapy and Nodal Response Rates in Luminal Breast Cancer: Effects of Age and Tumor Ki67.
    Boughey JC; Hoskin TL; Goetz MP
    Ann Surg Oncol; 2022 Sep; 29(9):5747-5756. PubMed ID: 35569077
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factors Associated with Pathological Node Negativity in Inflammatory Breast Cancer: Are There Patients Who May be Candidates for a De-Escalation of Axillary Surgery?
    Postlewait LM; Teshome M; DeSnyder SM; Lim B; Kuerer HM; Bedrosian I; Woodward WA; Ueno NT; Lucci A
    Ann Surg Oncol; 2020 Nov; 27(12):4603-4612. PubMed ID: 32710271
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Imaging response and residual metastatic axillary lymph node disease after neoadjuvant chemotherapy for primary breast cancer.
    Hieken TJ; Boughey JC; Jones KN; Shah SS; Glazebrook KN
    Ann Surg Oncol; 2013 Oct; 20(10):3199-204. PubMed ID: 23846781
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Axillary pathologic response after neoadjuvant chemotherapy and surgery according to breast cancers subtypes and survival impact.
    Jankowski C; Michel E; Vincent L; Beltjens F; Arnould L; Ladoire S; Coutant C
    Bull Cancer; 2023 Jun; 110(6):605-615. PubMed ID: 37080848
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcomes Following Neoadjuvant Chemotherapy for Breast Cancer in Women Aged 40 Years and Younger: Impact of Pathologic Nodal Response.
    Kozak MM; Jacobson CE; von Eyben R; Pollom EL; Telli M; Horst KC
    J Natl Compr Canc Netw; 2018 Jul; 16(7):845-850. PubMed ID: 30006427
    [No Abstract]   [Full Text] [Related]  

  • 30. Rates of pathologic nodal disease among cN0 and cN1 patients undergoing routine axillary ultrasound and neoadjuvant chemotherapy.
    Weiss A; King C; Vincuilla J; Parker T; Portnow L; Nakhlis F; Dominici L; Mittendorf EA; King TA
    Breast Cancer Res Treat; 2022 Sep; 195(2):181-189. PubMed ID: 35900704
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery.
    Tadros AB; Yang WT; Krishnamurthy S; Rauch GM; Smith BD; Valero V; Black DM; Lucci A; Caudle AS; DeSnyder SM; Teshome M; Barcenas CH; Miggins M; Adrada BE; Moseley T; Hwang RF; Hunt KK; Kuerer HM
    JAMA Surg; 2017 Jul; 152(7):665-670. PubMed ID: 28423171
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Surgical Management of the Axilla in Clinically Node-Positive Patients Receiving Neoadjuvant Chemotherapy: A National Cancer Database Analysis.
    Wong SM; Weiss A; Mittendorf EA; King TA; Golshan M
    Ann Surg Oncol; 2019 Oct; 26(11):3517-3525. PubMed ID: 31342389
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterizing Occult Nodal Disease Within a Clinically Node-Negative, Neoadjuvant Breast Cancer Population.
    Hammond JB; Scott DW; Kosiorek HE; Parnall TH; Gray RJ; Ernst BJ; Northfelt DW; McCullough AE; Ocal IT; Pockaj BA; Cronin PA
    Clin Breast Cancer; 2022 Feb; 22(2):186-190. PubMed ID: 34462208
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy.
    Kuerer HM; Sahin AA; Hunt KK; Newman LA; Breslin TM; Ames FC; Ross MI; Buzdar AU; Hortobagyi GN; Singletary SE
    Ann Surg; 1999 Jul; 230(1):72-8. PubMed ID: 10400039
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of higher axillary pathologic complete response rate with breast pathologic complete response after neoadjuvant chemotherapy.
    Zhu J; Li J; Fan Z; Wang H; Zhang J; Yin Y; Fu P; Geng C; Jin F; Jiang Z; Liu Z
    Ann Transl Med; 2020 Aug; 8(16):992. PubMed ID: 32953792
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Extent of axillary surgery in inflammatory breast cancer: a survival analysis of 3500 patients.
    Fayanju OM; Ren Y; Greenup RA; Plichta JK; Rosenberger LH; Force J; Suneja G; Devi GR; King TA; Nakhlis F; Hyslop T; Hwang ES
    Breast Cancer Res Treat; 2020 Feb; 180(1):207-217. PubMed ID: 31960171
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of neoadjuvant chemotherapy on pathologic axillary nodal status in HER-2 positive patients presenting with clinically node-negative disease.
    Al-Hilli Z; Hieken TJ; Hoskin TL; Heins CN; Boughey JC
    J Surg Oncol; 2015 Oct; 112(5):453-7. PubMed ID: 26345596
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of Neoadjuvant Chemotherapy on Nodal Disease and Nodal Surgery by Tumor Subtype.
    Al-Hilli Z; Hoskin TL; Day CN; Habermann EB; Boughey JC
    Ann Surg Oncol; 2018 Feb; 25(2):482-493. PubMed ID: 29181679
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic effect of nodal status before and after neoadjuvant chemotherapy in breast cancer: a Dutch population-based study.
    de Wild SR; Koppert LB; de Munck L; Vrancken Peeters MTFD; Siesling S; Smidt ML; Simons JM
    Breast Cancer Res Treat; 2024 Apr; 204(2):277-288. PubMed ID: 38133707
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nodal Response to Neoadjuvant Chemotherapy Predicts Receipt of Radiation Therapy After Breast Cancer Diagnosis.
    Fayanju OM; Ren Y; Suneja G; Thomas SM; Greenup RA; Plichta JK; Rosenberger LH; Force J; Hyslop T; Hwang ES
    Int J Radiat Oncol Biol Phys; 2020 Feb; 106(2):377-389. PubMed ID: 31678225
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.